BCAL Diagnostics Ltd
ASX:BDX
BCAL Diagnostics Ltd
Research & Development
BCAL Diagnostics Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
BCAL Diagnostics Ltd
ASX:BDX
|
Research & Development
-AU$4.5m
|
CAGR 3-Years
-33%
|
CAGR 5-Years
-57%
|
CAGR 10-Years
N/A
|
|
|
Opthea Ltd
ASX:OPT
|
Research & Development
-$126.8m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-60%
|
CAGR 10-Years
-37%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Research & Development
-$34.8m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
9%
|
CAGR 10-Years
6%
|
|
|
CSL Ltd
ASX:CSL
|
Research & Development
-$1.4B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-11%
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Research & Development
-AU$126.2m
|
CAGR 3-Years
-55%
|
CAGR 5-Years
-43%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Research & Development
-AU$70.1m
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-64%
|
CAGR 10-Years
-38%
|
|
BCAL Diagnostics Ltd
Glance View
BCAL Diagnostics Ltd. develops screening tests for the early detection of breast cancer. The company is headquartered in Sydney, New South Wales. The company went IPO on 2021-07-21. The firm is developing a blood screening test to improve the early diagnosis and monitoring of breast cancer that is safe, accurate and available to all women regardless of age, race and geographic location. The company has developed a non-invasive blood test for the detection of breast cancer. The firm is developing an in vitro diagnostic test (IVD) that confirms a fingerprint of lipid biomarkers extracted from extracellular vehicles (EVs) from a patient's plasma or blood sample to diagnose the presence of cancer cells in a patient’s body. BCAL has partnered with integrated cancer care and cardiac provider GenesisCare to conduct clinical research required for regulatory approvals across jurisdictions.
See Also
What is BCAL Diagnostics Ltd's Research & Development?
Research & Development
-4.5m
AUD
Based on the financial report for Jun 30, 2025, BCAL Diagnostics Ltd's Research & Development amounts to -4.5m AUD.
What is BCAL Diagnostics Ltd's Research & Development growth rate?
Research & Development CAGR 5Y
-57%
Over the last year, the Research & Development growth was -2%. The average annual Research & Development growth rates for BCAL Diagnostics Ltd have been -33% over the past three years , -57% over the past five years .
